Gollins, SimonWest, NickSebag-Montefiore, DavidMyint, Arthur SunSaunders, MarkSusnerwala, ShabbirQuirke, PhilEssapen, SharadahSamuel, LeslieSizer, BruceWorlding, JaneSouthward, KatieHemmings, GemmaTinkler-Hundal, EmmaTaylor, MoragBottomley, DanielChambers, PhilipLawrie, EmmaLopes, AndreBeare, Sandy2018-04-022018-04-022017-10-24Gollins, S, West, N, Sebag-Montefiore, D, Myint, A S, Saunders, M, Susnerwala, S, Quirke, P, Essapen, S, Samuel, L, Sizer, B, Worlding, J, Southward, K, Hemmings, G, Tinkler-Hundal, E, Taylor, M, Bottomley, D, Chambers, P, Lawrie, E, Lopes, A & Beare, S 2017, 'Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutations', British Journal of Cancer, vol. 117, pp. 1286-1294. https://doi.org/10.1038/bjc.2017.2940007-0920ORCID: /0000-0002-8402-8670/work/50559792http://hdl.handle.net/2164/10275This work was funded by Cancer Research UK Bobby Moore Fund (ref C23134A9353). Merck Serono supplied free cetuximab and an educational grant and Pfizer gave free irinotecan and an educational grant. Neither Merck Serono or Pfizer was involved in study design, data analysis or manuscript preparation or had access to study data. Central trial coordination was by Cancer Research UK and University College London Cancer Trials Centre, including data collection and statistical analyses. The Pathology and Tumour Biology laboratory is supported by grants from Yorkshire Cancer Research, the Pathological Society of Great Britain and Ireland, the Academy of Medical Sciences, The Medical Research Council and a National Institute of Health Research Senior Investigator Award. SG was a National Institute for Social Care and Health Research Academic Health Science Collaboration Clinical Research Fellow.9302187engSDG 3 - Good Health and Well-beinglocally advanced rectal cancercetuximab-containing chemoradiationRAS mutationsintra-tumoural clonal heterogeneitytreatment responsenext generation sequencingRC0254 Neoplasms. Tumors. Oncology (including Cancer)Cancer Research UKC23134A9353RC0254Journal article10.1038/bjc.2017.294117